Imatinib is the frontline drug of choice in 55% of Italian patients with CP-CML, with 2G-TKIs prevalently used in younger patients and in those with no concomitant clinical conditions . The choice of TKI therapy is based on a combined evaluation of the patient’s and the disease characteristics .